Cortavance 31Ml

Target species Dogs Indications for use For symptomatic treatment of inflammatory and pruritic dermatoses in dogs. Contra-indications Do not use on cutaneous ulcers. Special warnings for each target species Total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise, use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations. Special precautions for use in animals In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such conditions. In the absence of specific information, the use in animals suffering from Cushing’s syndrome shall be based on the risk-benefit assessment. Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations. In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental skin contact, it is recommended to wash thoroughly with water. Wash hands after use. Avoid contact with eyes. In case of accidental eye contact, rinse with abundant quantities of water. In case of eye irritation, seek medical advice. In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician. Spray preferably in a well ventilated area. Flammable. Do not spray on naked flame or any incandescent material. Do not smoke while handling the veterinary medicinal product. Use during pregnancy or lactation The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs. Use only according to the risk-benefit assessment by the responsible veterinarian. Interactions In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.